Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here to find out why GERN stock is a Buy.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

as well as in anaemia failing an erythropoiesis stimulating agent that requires two or more RBC units over eight week in adult patients with IPSS-R myelodyplastic syndrome with ring sideroblasts ...

Moreover, while Reblozyl was only cleared for use as second-line therapy in MDS patients with ring sideroblasts – blood cells with a characteristic circle of iron deposits around their nucleus ...

Treatment modalities in such candidates include hematopoietic growth factors, luspatercept in candidates with ring sideroblasts, epigenetic modifiers, erythrocyte transfusions, and immunosuppressive ...

1 % of blasts were identified, and an increase of medullar iron was present with no ringed sideroblasts. Immunohistochemical analysis with CD61 made micro-megakaryocytes highlighted dysplastic ...

Erythroblasts possess unique characteristics as they undergo differentiation from hematopoietic stem cells. During terminal erythropoiesis, these cells incorporate large amounts of iron in order to ...

The Martin Jädersten group is investigating biological and clinical aspects of acute myeloid leukemia (AML) and runs academic trials exploring novel treatment strategies. The team leader Martin ...